We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Rapid Diagnostic System to Deliver Same-Shift Antibiotic Susceptibility Test Results

By LabMedica International staff writers
Posted on 20 Aug 2024

The World Health Organization estimates that sepsis impacts around 49 million people worldwide each year, resulting in roughly 11 million deaths, with about 1. More...

32 million of these deaths directly linked to bacterial antimicrobial resistance. Given the urgency, there's a growing need for rapid antimicrobial susceptibility testing (AST) that can guide the use of targeted antimicrobial therapies. Such testing is crucial for enhancing patient outcomes, reducing hospital costs, and curbing the rise of antimicrobial resistance. Now, a rapid AST system aims to deliver same-shift results, significantly aiding antimicrobial stewardship teams and clinicians in promptly customizing treatments for patients with severe infections.

The WAVE system from Accelerate Diagnostics (Tucson, AZ, US) is designed to deliver rapid AST results from positive blood culture (PBC) bottles and isolated bacterial colonies (isolates), delivering precise results in approximately 4.5 hours. Utilizing cutting-edge holographic imaging technology, the WAVE system tracks bacterial growth and morphology changes in real-time, thus allowing for quick, quantitative susceptibility test outcomes. It features a comprehensive test menu and integrates key functionalities to enhance laboratory workflows. The system's full random access capability supports continuous sample loading, making it adaptable for a wide range of healthcare environments, from small community hospitals to large academic and reference laboratories.

Accelerate Diagnostics has concluded a pre-clinical trial of the WAVE system, which involved a comparative analysis of 1,570 WAVE results against those obtained via broth microdilution, the gold standard reference method. The trial incorporated an equal mix of prospective patient samples and specifically chosen challenge samples, yielding high concordance rates between the different sample types. The trial's summary data showed an essential agreement and categorical agreement rate of about 95%, demonstrating the system's effectiveness.

“We are extremely pleased to announce the goals for our WAVE pre-clinical trial were achieved with strong performance and unprecedented time-to-result of 4.5-hours, on average, along with strong instrument reliability and assay reportability,” said Jack Phillips, President and CEO of Accelerate Diagnostics, Inc. “With the success of the pre-clinical trial we have confidence in both our WAVE product design and the system capabilities to move to a clinical trial and in turn commercialize.”

Related Links:
Accelerate Diagnostics


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Respiratory Syncytial Virus Test
OSOM® RSV Test
New
Vasculitis Diagnostic Test
AESKULISA Vasculitis-Screen
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Ear wax could be a possible screening medium for Parkinson’s disease (Photo courtesy of 123RF)

Earwax Test Accurately Detects Parkinson’s by Identifying Odor Molecules

Current tests for Parkinson’s disease (PD) rely heavily on clinical scales and neuroimaging, which are often subjective, expensive, and ill-suited for routine screening. Since most treatments only slow... Read more

Molecular Diagnostics

view channel
Image: Capsule sponge opened to reveal the sponge (Photo courtesy of StillVision)

Capsule Sponge Test Could Replace Endoscopies for Monitoring Esophageal Cancer Risk

Esophageal cancer remains a challenging disease to treat, with fewer than 20% of patients surviving beyond five years of diagnosis—a statistic that has remained largely unchanged for decades.... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The new tool shines a light on elusive genomic patterns (Photo courtesy of Adobe Stock)

Computational Tool Exposes Hidden Cancer DNA Changes Influencing Treatment Resistance

Structural changes in tumor DNA are among the most damaging genetic alterations in cancer, yet they often go undetected, particularly when tissue samples are degraded or of low quality. These hidden genomic... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.